Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial
ILIrene L. M. ReijersAMAlexander M. MenziesACAlexander C. J. van AkkooiJMJudith M. VersluisNVN.M.J. Van Den Heuvel
The Netherlands Cancer Institute · The University of Sydney · +13 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
347
total citations
- FWCI
- 31.30
- Percentile
- 100%
- References
- 37
Citations per year
Authors
38- ILIrene L. M. ReijersCorresponding
The Netherlands Cancer Institute
- AMAlexander M. Menzies
The University of Sydney, Royal North Shore Hospital, Melanoma Institute Australia
- ACAlexander C. J. van Akkooi
The University of Sydney, The Netherlands Cancer Institute, Oncode Institute, Melanoma Institute Australia
- JMJudith M. Versluis
The Netherlands Cancer Institute
- NVN.M.J. Van Den Heuvel
The Netherlands Cancer Institute
Topics & keywords
Topics
Keywords
- Medicine
- Ipilimumab
- Nivolumab
- Oncology
- Lymph node
- Neoadjuvant therapy
- Internal medicine
- Stage (stratigraphy)
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- BSBristol-Myers Squibb
- ULUniversiteit Leiden
- UOUniversity of Sydney
- EMErasmus Medisch Centrum
- LULeids Universitair Medisch Centrum
- UMUniversitair Medisch Centrum Groningen
- MIMelanoma Institute Australia
- MRMedical Research Council
- NHNational Health and Medical Research Council
- SMSydney Medical School Foundation